Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.
Royal University Hospital, Saskatoon, Saskatchewan, Canada
Rush University Medical Center, Chicago, Illinois, United States
Zealand university Hospital, Anaesthesiology, Roskilde, Denmark
Zealand University Hospital, Department of Anaesthesiology, Roskilde, Denmark
VinMec Central park International hospital, Ho Chi Minh City, Vietnam
Sturgeon Community Hospital, St. Albert, Alberta, Canada
University of Alberta Hospital, Edmonton, Alberta, Canada
University of Minnesota, Minneapolis, Minnesota, United States
ShenZhen People's Hospital of Jinan University, Shenzhen, Guangdong, China
Hospital Universiti Sains Malaysia (HUSM), Kubang Kerian, Kelantan, Malaysia
Milton S.Hershey Medical center, Hershey, Pennsylvania, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.